Menu
×
Don't Miss Out!
Get your weekly Breakfast Briefing eNewsletter, filled with news, trends, and vital information from DIA!
DIA 2021 Global Annual Meeting
A Collaborative Cross-Company Pediatric Platform Trial in Pediatric Crohn’s Disease Using an Innovative Bayesian Analysis
Session Chair(s)
Robert Nelson, MD, PhD
- Senior Director, Pediatric Drug Development (CHILD)
- Johnson & Johnson, United States
Innovative approaches to pediatric drug development are needed to reduce the delay between adult and pediatric marketing approval. This session presents a cross-company pediatric platform trial in Crohn's disease using a Bayesian analysis.
Learning Objective : Identify some of the recruitment challenges in pediatric drug development; Identify the role of platform trials in addressing these challenges; Discuss the clinical, scientific, regulatory, and operational challenges in designing and implementing a cross-company pediatric platform trial.
Speaker(s)

Industry Update
Laurie Conklin, DrMed, MD
- Director, Pediatric Immunology
- Janssen, United States
Industry Update
Wendy Komocsar
- Research Advisor, Immunology
- Eli Lilly and Company , United States

Industry Update
Forrest Williamson, PhD
- Senior Research Scientist, Statistics Data and Analytics
- Eli Lilly and Company, United States